stockrow
Saturday 7 November 2026
Export ACTU’s income statement to Excel — free account
Actuate Therapeutics, Inc.
ACTU Healthcare Biotechnology
- EPS
- +33.3%
- Free cash flow
- −5.54%
Quarter to June 2026, against a year earlier
0.33
0.00
0.00%
Follow ACTU
Alert me
Actuate Therapeutics, Inc. (ACTU) P/E ratio
Actuate Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. | n/m |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| COCP Cocrystal Pharma, Inc. compare | n/m |
| BSEM BioStem Technologies, Inc. compare | n/m |
| QNTM Quantum Biopharma Ltd. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)